Antibody-Drug Conjugates

Bladder Cancer Highlights ASCO
Seagen/Astellas plans to expand their Antibody Drug Conjugate (ADC), Padcev in additional bladder...

Padcev (Enfortumab vedotin) for the treatment of locally advanced or metastatic urothelial cancer, Adcetris (Brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas, a...


antibody-drug-conjugate-pipeline
Insights into the Evolving Landscape of Antibody-Drug Conjugate (ADC) & the Key Companies in...

In the year 2000, the first-ever Antibody-drug Conjugate (ADC) - Mylotarg, was launched by Pfizer and was considered a miracle in cancer treatment. And it appeared like there was no looking back f...


Intellia's Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly's Diabetes Blockbuster Tirzepatide; Polyphor’s Bleak Future
Intellia’s Quest with CRISPR; Innovent, Synaffix ADC Tech Deal; Lilly’s Diabetes Bloc...

A New Dawn for CRISPR, Intellia Edits Cells Inside the Body Intellia Therapeutics, along with its partner Regeneron Pharmaceuticals, recently announced its successful attempt in editing the cel...


Johnson & Johnson
4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent Bio...

Gene therapy company 4D Molecular Therapeutics raises USD 90 Million to collaborate with AstraZeneca and Roche for moving gene therapies into clinical testing 4D Molecular Therapeutics has uprais...


Default Blog Image
Sutro nets $85.4M; HiFiBiO pens Takeda R&D collaboration

Sutro Biopharma nets $85.4M to drive antibody-drug conjugates Sutro Biopharma reeled in an $85.4 million series E that will advance some early-stage programs as well as its cancer pipeline, which i...


The next generation of ‘weaponized antibody’ therapies

Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam. The next generation of these ‘weaponized antibody’ therapies, called ...


DelveInsight’s Oncology based Reports, 2015

DelveInsight, the leading market research and consulting company has added Oncology based Reports to its portfolio. With this launch DelveInsight now has 100+ Oncology based Reports. In addition to...


Default Blog Image
Antibody-Drug Conjugate and Big Pharmaceutical Companies

Antibody Drug Conjugate and Big Pharmaceutical Companies Boom Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments ...


Default Blog Image
Next Generation Antibody-Drug Conjugate Therapeutics and Market Analysis

Antibody-Drug Conjugates-A Big Boom! Therapeutics developed to create innovative medicines based on the use of new and improved antibodies is the next generation cure for the treatment of variou...


Default Blog Image
Antibody-Drug Conjugates Market Outlook, 2015 Report

264 Antibody-Drug Conjugates in Pipeline!!!! Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billion...


Editor's Pick
Can denovoSkin Be A Lifesaver for Burn Victims?

Burn is a global public health problem, causing more than 180,000 deaths per year acros...

NexoBrid and its Awaiting US Approval

A Burn takes place when the skin comes into contact with a heat source. Burns can occur...

New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Do...

Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...

Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.